A multimodal HPLC stability indicating approach for the estimation of Semaglutide and Tirzepatide in bulk, pharmaceutical dosage forms, and rat plasma: a six-edged sustainability appraisal.
BMC Chem · 2026
Last updated 2026-05-28Researchers developed a lab method to measure the amounts of two GLP-1 drugs, Semaglutide and Tirzepatide, in pills and rat blood. The test can detect very small amounts—10 ng/mL for Tirzepatide and 16 ng/mL for Semaglutide—and works across a wide range from 1 to 500 µg/mL. The method was also tested under harsh conditions like acid, base, light, and oxidation to ensure it remains accurate.
AI summary of the abstract below.
| Journal | BMC Chem, 2026 |
|---|---|
| Citations | 0 |
| Molecules | semaglutide, tirzepatide |
| Conditions studied | Type 2 Diabetes, Obesity |
Abstract
Over the recent years, there has been a notable surge in consumer demand for rapid and effective weight-loss pharmaceuticals that are also capable of managing type 2 diabetes. Owing to their exceptional efficacy, GLP-1 receptor agonists, including Tirzepatide (TIR) and Semaglutide (SEM), have had phenomenal outcomes and confidence among consumers. A rapid, straightforward, and thorough approach for quantifying SEM and TIR is essential for quality control purposes given the rising use of these drugs in the pharmaceutical industry. This work presents the first stability-indicating HPLC method for quantifying TIR and SEM under various stress conditions (acidic and basic hydrolysis, oxidative, and photolytic degradation) without interference from degradants. In addition, the proposed methods are capable of accurately quantifying each drug in bulk, pharmaceutical dosage forms, and spiked plasma. The analysis of TIR and SEM was performed using an Inertsil ODS-3 (4.6 × 250 mm, 5 μm particle size) C18 column and the elution of the drugs was achieved isocratically using 0.1% formic acid (pH 2.5) and ACN in the ratio 30:70 with a flow rate 1 mL/min using DAD detector at 220 nm with SEM and TIR eluting at 1.42 and 1.68 min respectively. The proposed method was validated in line with the International Conference of Harmonization (ICH) guidelines and has demonstrated excellent accuracy, linearity, and superior sensitivity with LOD values of 10 and 16 ng/mL for TIR and for SEM, respectively. The obtained linearity range for both TIR and SEM was 1-500 µg/mL with correlation coefficients > 0.9999. An in-depth six- edged sustainability assessment of the proposed method was conducted using greenness, whiteness, blueness and violet innovation metrics was performed using Analytical Greenness Metric (AGREE), Modified Green Analytical Procedure Index (MoGAPI), Analytical Eco-scale, Analytical Green Star Area (AGSA), Carbon Footprint Reduction Index (CaFRI), Whiteness using RGB algorithm, Blue Applicability Grade Index (BAGI), Click Analytical Chemistry Index (CACI), Violet Innovation Grade Index (VIGI) tools and Stability Toolkit for the Appraisal of Bio/Pharmaceuticals' Level of Endurance (STABLE).
Verbatim abstract via PubMed 41588418 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.